Literature DB >> 12023213

Homology modeling and molecular dynamics study of NAD-dependent glycerol-3-phosphate dehydrogenase from Trypanosoma brucei rhodesiense, a potential target enzyme for anti-sleeping sickness drug development.

Igor Z Zubrzycki1.   

Abstract

Sleeping sickness and Chagas disease are among the most severe diseases in Africa as well as Latin America. These two diseases are caused by Trypanosoma spp. Recently, an enzyme of a glycolytic pathway, NAD-dependent glycerol-3-phosphate dehydrogenase, of Leishmania mexicana was crystallized and its structure determined by x-ray crystallography. This structure has offered an excellent template for modeling of the homologous enzymes from another Trypanosoma species. Here, a homology model of the T. brucei enzyme based on the x-ray structure of LmGPDH has been generated. This model was used as the starting point for molecular dynamics simulation in a water box. The analysis of the molecular dynamics trajectory indicates that the functionally important motifs have both a very stable secondary structure and tertiary arrangement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023213      PMCID: PMC1302078          DOI: 10.1016/S0006-3495(02)75631-2

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  31 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Protein modelling for all.

Authors:  N Guex; A Diemand; M C Peitsch
Journal:  Trends Biochem Sci       Date:  1999-09       Impact factor: 13.807

Review 3.  Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.

Authors:  M P Barrett; J C Mottram; G H Coombs
Journal:  Trends Microbiol       Date:  1999-02       Impact factor: 17.079

4.  The fall and rise of sleeping sickness.

Authors:  M P Barrett
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

5.  The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000.

Authors:  A Bairoch; R Apweiler
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

6.  Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase.

Authors:  A M Aronov; S Suresh; F S Buckner; W C Van Voorhis; C L Verlinde; F R Opperdoes; W G Hol; M H Gelb
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  Homology modeling, model and software evaluation: three related resources.

Authors:  R Rodriguez; G Chinea; N Lopez; T Pons; G Vriend
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

8.  Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan.

Authors:  H Denise; C Giroud; M P Barrett; T Baltz
Journal:  Eur J Biochem       Date:  1999-01

9.  Resurgence of sleeping sickness in Tambura County, Sudan.

Authors:  A Moore; M Richer; M Enrile; E Losio; J Roberts; D Levy
Journal:  Am J Trop Med Hyg       Date:  1999-08       Impact factor: 2.345

10.  A bisubstrate analog induces unexpected conformational changes in phosphoglycerate kinase from Trypanosoma brucei.

Authors:  B E Bernstein; D M Williams; J C Bressi; P Kuhn; M H Gelb; G M Blackburn; W G Hol
Journal:  J Mol Biol       Date:  1998-06-26       Impact factor: 5.469

View more
  2 in total

1.  The studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-beta-glucosidase.

Authors:  Igor Z Zubrzycki; Agnieszka Borcz; Magdalena Wiacek; Wojciech Hagner
Journal:  J Mol Model       Date:  2007-08-23       Impact factor: 1.810

2.  Structural analysis of trypanosomal sirtuin: an insight for selective drug design.

Authors:  Simranjeet Kaur; Amol V Shivange; Nilanjan Roy
Journal:  Mol Divers       Date:  2009-04-29       Impact factor: 2.943

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.